Orencia

For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthrit...

Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA

...ade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that Actemra would be most likely to replace BMS's orencia in their practices. LaunchTrends (TM) measure launch effectiveness of new products from FDA approval through six months post launch. The next...

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...sent day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as Rituxan and orencia made significant inroads by addressing therapeutic needs not addressed by existing drugs. The global marketplace is characterized by participants ...

Rheumatoid Arthritis Drug Might Fight Swine Flu

...ia, and the U.S. National Institutes of Health. orencia was approved for use in the United States in 2005 ...before the mice actually fell ill, half were given orencia while the remaining half were left untreated. In both sets of mice, those that had received orencia cleared the virus quicker, got less sick and recov...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

... Japan until the arrival of Bristol-Myers Squibb's orencia in 2012, and the likelihood that the drug will be ...ve agents with other mechanisms of action, such as orencia and Biogen Idec/Genentech's Rituxan (also marketed...in promotional spend coinciding with the launch of orencia and Rituxan, these relatively new entrants are str...

Drug May Ease Symptoms of Juvenile Arthritis

...th other treatments may benefit from a drug called orencia (abatacept). The conclusions follow from a rand... assigned to receive 10 milligrams per kilogram of orencia at 28-day intervals for six months or until the ar...patients on the placebo and 20 percent of those on orencia experienced an exacerbation of their condition. Th...

Celebrity Chef Sandra Lee Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis

...small dinner party with friends," continued Lee. orencia is a prescription medicine used to treat adults wi...tol-Myers Squibb. About ORENCIA(R) (abatacept) orencia is a prescription medicine that is used to treat a... even though they may have tried other treatments. orencia can be used alone or with other agents....

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

... 462 362 28 % 361 294 23 % 11 % Immunoscience orencia 75 32 134 % 66 31 113 % N/A Other Pharm... 1,660 1,282 29 % 1,305 1,052 24 % 12 % Immunoscience orencia 231 89 160 % 216 88 145 % N/A Other Phar...

Orencia in Medical Technology

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results regarding the efficacy and safety of ORENCIA(R) (abatacept) from the open-label phase of an ongoing investigational study in children with juvenile idiopathic arthritis (JIA) who have had...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... - orencia is a First-in-Class Biologic Treatment Option Now ...therapy, such as anakinra. This new indication for orencia provides significant evidence of its durable effic...three-part study through one year. The approval of orencia in JIA represents the ongoing commitment of Bristo...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

... n=219 for placebo plus MTX) and ATTAIN (n=258 for orencia plus DMARDs; n=133 for placebo plus DMARDs) studie...tion questionnaire. Patients who were treated with orencia were compared with those in the placebo group. Thi...pate in daily activities in AIM was 61 percent for orencia vs. 46 percent for placebo at one year, and in ATT...

Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate

...xate (MTX). The data show that, in these patients, orencia provided sustained improvements in ACR responses, ...ion rates observed in this study, demonstrate that orencia provides durable long-term clinical benefits in pa...ontrolled randomized trial received MTX and either orencia (10 mg/kg or 2 mg/kg) or placebo administered as a...

ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review

...n which all participants (6-17 years old) received orencia and both clinical response and safety were assesse...thdrawal phase in which responders received either orencia or placebo and time to disease flare and safety we...en- label phase in which all participants received orencia in order to assess long-term efficacy and safety (...

Orencia in Biological Technology

Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?

...d a higher percent of Rheumatologists report using orencia this year compared to last. Despite these gains, t...cket costs to patients, a top obstacle to expanded orencia use is its second/third line status ("patients do ...ng Rituxan for RA. Most respondents indicated that orencia is typically chosen after one TNF-alpha failure wh...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... - N/A Affective (Psychiatric) Disorders Abilify (total revenue) 454 366 24% 348 293 19% 14% Immunoscience orencia 87 41 112% 73 40 83% N/A Nutritionals Enfamil 290 254 14% 183 171 7% ...

Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report

...Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Scheri...